Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
10:56am, Friday, 13'th Dec 2024
The consensus price target hints at a 48% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning
Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?
06:48am, Monday, 09'th Dec 2024
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Friday, 29'th Nov 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the “Grant Date�
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
03:01pm, Friday, 29'th Nov 2024
The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
12:35pm, Wednesday, 27'th Nov 2024
Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet
11:00am, Wednesday, 27'th Nov 2024
The mean of analysts' price targets for Sarepta Therapeutics (SRPT) points to a 42.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration
Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step
03:02pm, Friday, 08'th Nov 2024
Sarepta Therapeutics, Inc. reported Q3 2024 net product revenues of $429.8 million, a 39% year-over-year increase, driven by strong sales of ELEVIDYS and other DMD treatments. The company is advancing
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
10:20am, Thursday, 07'th Nov 2024
Sarepta posts encouraging Q3 earnings. After conducting a risk-benefit analysis, the company decides to stop developing the entire PPMO program.
Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript
02:10am, Thursday, 07'th Nov 2024
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communic
Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
07:36pm, Wednesday, 06'th Nov 2024
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
08:30am, Wednesday, 23'rd Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2024 financial results after the Nasd
2 High-Flying Growth Stocks With Massive Upside Potential
09:53am, Thursday, 17'th Oct 2024
These innovative drugmakers have potential catalysts ahead.
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
08:15am, Thursday, 03'rd Oct 2024
These two could become direct competitors relatively soon.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:39pm, Monday, 30'th Sep 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2024 (the “Grant Date�
